Does the vehicle change how much topical finasteride is absorbed?

Topical finasteride is a prescription medication, and the way a formula is put together affects how much of the drug crosses the skin. This article summarises what formulation sources say about solvents and vehicles. It is background reading, not a formulation guide: the strength, vehicle and application schedule of a topical finasteride product are decisions for the prescriber or compounding pharmacist.

What is a solvent?

A solvent is a substance that dissolves another substance to form a uniform mixture. In topical products, solvents help active ingredients such as finasteride distribute evenly and cross the skin barrier. The solvent a formulation uses is one of the things that determines how much drug is absorbed.

Why does absorption matter for finasteride?

Finasteride blocks DHT (dihydrotestosterone), the hormone that causes susceptible hair follicles to shrink and produce progressively finer hairs. Taken orally, finasteride enters the bloodstream and lowers DHT throughout the body. Applied topically, it has to cross the scalp skin to reach the follicles. If very little is absorbed, there may be little local effect.

Absorption is not simply "more is better". Topical finasteride does not stay in the scalp: studies of topical formulations have measured reductions in blood DHT in users, which means some of the drug reaches the circulation. Anything that increases how much crosses the skin also increases that systemic exposure and, with it, the potential for the same side effects reported with oral finasteride: the US label lists sexual, mood and suicidal-thought, breast and semen effects, some of which men reported continuing after stopping. Those entries come from voluntary reports, which cannot show how often they occur or prove cause; the FAQ "Is finasteride safe?" covers the full range and its limits. This is why the formulation is a prescribing decision rather than something to optimise at home.

Propylene glycol: a common vehicle

Formulation literature describes propylene glycol as a common ingredient in finasteride creams and solutions because it acts as a penetration enhancer, carrying the drug into the deeper layers of the skin. It is widely used in dermatological products for this reason.

Propylene glycol is also a recognised cause of skin irritation and, in some people, allergic contact dermatitis. Scalp itching, redness or stinging with a propylene-glycol vehicle is a reason to speak to the prescriber about an alternative rather than to continue.

Microemulsions: a more advanced alternative

Microemulsions are a formulation technology used to improve absorption of active ingredients. They are mixtures of water, oil and surfactants that disperse the drug in very small droplets, which can improve how quickly and completely it is released into the skin.

A 2019 laboratory study reported that finasteride microemulsions increased how much of the drug passed through rat skin in vitro. These are formulation studies, and better penetration in the laboratory has not been shown to mean better hair outcomes in people. The clinical evidence for topical finasteride as a treatment comes from trials of specific products, such as a 24-week trial of a finasteride spray authorised in Europe, not from vehicle comparisons; a trial that short cannot say anything about effects after stopping. In the US there is no FDA-approved topical finasteride; compounded versions have not been evaluated by the FDA, which issued a safety alert about them in April 2025. The alert cited 32 reports received between 2019 and 2024 of erectile dysfunction, decreased libido, anxiety, depression, suicidal thoughts, brain fog, fatigue, insomnia and testicular pain, most of which were said to continue after people stopped using the product; a few dozen voluntary reports cannot show how often this happens or whether the product caused it.

Other factors that affect absorption of topical finasteride

Beyond the vehicle, formulation and dermatology sources note several factors that influence how much of a topical drug is absorbed:

Scalp condition: A clean scalp, free of heavy oil or product residue, generally absorbs topical products more consistently. Broken, inflamed or freshly shaved skin absorbs considerably more, which is a reason to be careful rather than a technique to use.

Exfoliating and keratolytic agents: Ingredients such as salicylic acid remove surface cells and can increase how much of a co-applied drug is absorbed. With a hormonally active drug like finasteride this raises systemic exposure and side-effect risk, so combining them is something to ask a prescriber about, not to try independently.

Exposure time: Leaving the product on the scalp for the time the product instructions specify allows the intended amount of absorption.

Application frequency: Use the schedule on the prescription. Applying more often, or more product, does not reliably improve results and does increase systemic exposure.

Conclusion

Formulation sources agree that the vehicle matters: propylene glycol and microemulsion systems are described as improving how much finasteride crosses the skin. What that evidence does not show is that a more penetrating formula produces better hair results in people, and it comes with a trade-off, because more absorption also means more of the drug reaching the bloodstream.

Talk to a doctor or pharmacist before starting, stopping or combining topical finasteride, and before adding anything to your routine intended to increase its absorption. The choice of vehicle and strength should come from whoever prescribes or compounds it. Topical finasteride carries the same pregnancy warning as the oral drug: women who are pregnant or may become pregnant should not handle or be exposed to it.

sources

Organon. PROPECIA (finasteride) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

Mohammad Soleymani, S., & Salimi, A. (2019). Enhancement of dermal delivery of finasteride using microemulsion systems. Advanced Pharmaceutical Bulletin, 9(4), 584-592. https://pubmed.ncbi.nlm.nih.gov/31857962/

US Food and Drug Administration (2025, April 22). FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded

Garcia-Hernandez, M.J., Camacho Martinez, F.M., & Moreno Gimenez, J.C. (2016). Therapeutic advances in trichology. Actas Dermo-Sifiliograficas, 107(9), 772-784. https://www.actasdermo.org/es-novedades-terapeuticas-tricologia-articulo-resumen-S0001731016304379

Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(2), 286-294. https://pubmed.ncbi.nlm.nih.gov/34634163/